ES2213922T3 - Formulaciones y metodos para reducir la toxicidad de agentes antineoplasticos. - Google Patents
Formulaciones y metodos para reducir la toxicidad de agentes antineoplasticos.Info
- Publication number
- ES2213922T3 ES2213922T3 ES98953570T ES98953570T ES2213922T3 ES 2213922 T3 ES2213922 T3 ES 2213922T3 ES 98953570 T ES98953570 T ES 98953570T ES 98953570 T ES98953570 T ES 98953570T ES 2213922 T3 ES2213922 T3 ES 2213922T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- taxane
- compound
- administration
- antineoplastic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 73
- 239000002246 antineoplastic agent Substances 0.000 title abstract description 64
- 230000001988 toxicity Effects 0.000 title abstract description 48
- 231100000419 toxicity Toxicity 0.000 title abstract description 48
- 229940034982 antineoplastic agent Drugs 0.000 title abstract description 43
- 238000000034 method Methods 0.000 title abstract description 29
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 125000003396 thiol group Chemical group [H]S* 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 229940123237 Taxane Drugs 0.000 claims description 77
- 238000009472 formulation Methods 0.000 claims description 62
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 55
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- KQYGMURBTJPBPQ-UHFFFAOYSA-L disodium;2-(2-sulfonatoethyldisulfanyl)ethanesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)CCSSCCS([O-])(=O)=O KQYGMURBTJPBPQ-UHFFFAOYSA-L 0.000 claims description 30
- 239000003795 chemical substances by application Substances 0.000 claims description 28
- 229950009278 dimesna Drugs 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 21
- 150000003057 platinum Chemical class 0.000 claims description 20
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 238000004090 dissolution Methods 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 229940100198 alkylating agent Drugs 0.000 claims description 6
- 239000002168 alkylating agent Substances 0.000 claims description 6
- 238000011260 co-administration Methods 0.000 claims description 6
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 3
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 2
- 229910001413 alkali metal ion Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical compound C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 claims description 2
- 230000003432 anti-folate effect Effects 0.000 claims description 2
- 229940127074 antifolate Drugs 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 150000005699 fluoropyrimidines Chemical class 0.000 claims description 2
- 239000004052 folic acid antagonist Substances 0.000 claims description 2
- 230000003054 hormonal effect Effects 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 2
- IEPCYJLTAGEWNI-CULQTAMWSA-N (5s,5ar)-5-[[(2r)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3[C@@H](OC3C(C(O)C4O[C@H](C)OCC4O3)O)[C@@H]3C2C(OC3)=O)=C1 IEPCYJLTAGEWNI-CULQTAMWSA-N 0.000 claims 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 239000013059 antihormonal agent Substances 0.000 claims 1
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 239000012039 electrophile Substances 0.000 claims 1
- 239000002786 epipodophyllotoxin derivative Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 19
- 239000003223 protective agent Substances 0.000 abstract description 13
- 150000002019 disulfides Chemical class 0.000 abstract description 2
- 229960004316 cisplatin Drugs 0.000 description 58
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 53
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- BYUKOOOZTSTOOH-UHFFFAOYSA-N 2-(2-sulfoethyldisulfanyl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCSSCCS(O)(=O)=O BYUKOOOZTSTOOH-UHFFFAOYSA-N 0.000 description 44
- 239000003814 drug Substances 0.000 description 39
- 229940079593 drug Drugs 0.000 description 37
- 230000000694 effects Effects 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 235000002639 sodium chloride Nutrition 0.000 description 23
- 231100000331 toxic Toxicity 0.000 description 23
- 230000002588 toxic effect Effects 0.000 description 23
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- 239000011780 sodium chloride Substances 0.000 description 20
- 229960004635 mesna Drugs 0.000 description 19
- 230000007246 mechanism Effects 0.000 description 18
- 239000008174 sterile solution Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 239000000126 substance Substances 0.000 description 13
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 12
- 229960004562 carboplatin Drugs 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 230000009471 action Effects 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 210000004688 microtubule Anatomy 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
- 239000008227 sterile water for injection Substances 0.000 description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000010944 pre-mature reactiony Methods 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 229940044684 anti-microtubule agent Drugs 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000009096 combination chemotherapy Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- 229960001101 ifosfamide Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001012 protector Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241001116498 Taxus baccata Species 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- -1 chlorine ions Chemical class 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 231100000226 haematotoxicity Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 238000002638 palliative care Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- HZSBSRAVNBUZRA-RQDPQJJXSA-J (1r,2r)-cyclohexane-1,2-diamine;tetrachloroplatinum(2+) Chemical compound Cl[Pt+2](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N HZSBSRAVNBUZRA-RQDPQJJXSA-J 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical compound N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003388 anti-hormonal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-O aziridinium Chemical compound C1C[NH2+]1 NOWKCMXCCJGMRR-UHFFFAOYSA-O 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000034404 cisplatin toxicity Diseases 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical class [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002828 effect on organs or tissue Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229950008017 ormaplatin Drugs 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000735 select agent Toxicity 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/954,678 US5919816A (en) | 1994-11-14 | 1997-10-17 | Formulations and methods of reducing toxicity of antineoplastic agents |
| US954678 | 1997-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2213922T3 true ES2213922T3 (es) | 2004-09-01 |
Family
ID=25495777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98953570T Expired - Lifetime ES2213922T3 (es) | 1997-10-17 | 1998-10-16 | Formulaciones y metodos para reducir la toxicidad de agentes antineoplasticos. |
Country Status (12)
| Country | Link |
|---|---|
| US (11) | US5919816A (enExample) |
| EP (1) | EP1033981B1 (enExample) |
| JP (3) | JP2001520189A (enExample) |
| CN (1) | CN1276720A (enExample) |
| AT (1) | ATE262329T1 (enExample) |
| AU (1) | AU750521B2 (enExample) |
| CA (1) | CA2304704C (enExample) |
| DE (1) | DE69822659T2 (enExample) |
| DK (1) | DK1033981T3 (enExample) |
| ES (1) | ES2213922T3 (enExample) |
| PT (1) | PT1033981E (enExample) |
| WO (1) | WO1999020264A1 (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US8853260B2 (en) * | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20020155999A1 (en) * | 1998-04-30 | 2002-10-24 | Han In Suk | Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer |
| US7314637B1 (en) | 1999-06-29 | 2008-01-01 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
| US6075053A (en) * | 1999-02-09 | 2000-06-13 | Bionumerik Pharmaceuticals, Inc. | Method of reducing or reversing neuropathy |
| US6197831B1 (en) * | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
| US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
| US20030036513A1 (en) * | 1999-02-16 | 2003-02-20 | Yurkow Edward J. | Method for treating cancer |
| GB9904386D0 (en) * | 1999-02-25 | 1999-04-21 | Pharmacia & Upjohn Spa | Antitumour synergistic composition |
| US6664288B1 (en) * | 1999-04-14 | 2003-12-16 | Dana Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
| US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
| US20050222246A1 (en) * | 1999-04-14 | 2005-10-06 | Li Chiang J | Beta-lapachone is a broad spectrum anti-cancer agent |
| WO2000064437A1 (en) * | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| US6034126A (en) * | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
| GB9916882D0 (en) * | 1999-07-19 | 1999-09-22 | Pharmacia & Upjohn Spa | Antitumor synergistic composition |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP1231984A1 (en) * | 1999-11-15 | 2002-08-21 | Parker Hughes Institute | Phorboxazole derivatives for treating cancer |
| US6890946B2 (en) * | 1999-12-23 | 2005-05-10 | Indiana University Research And Technology Corporation | Use of parthenolide to inhibit cancer |
| WO2001070220A1 (en) * | 2000-03-22 | 2001-09-27 | Neopharm, Inc. | A method of administering liposomal encapsulated taxane |
| GB0011927D0 (en) * | 2000-05-17 | 2000-07-05 | Inst Biomar Sa | New use of citreamicins |
| GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
| US20050197405A1 (en) * | 2000-11-07 | 2005-09-08 | Li Chiang J. | Treatment of hematologic tumors and cancers with beta-lapachone, a broad spectrum anti-cancer agent |
| MXPA03004095A (es) | 2000-11-09 | 2004-09-10 | Neopharm Inc | Complejos de sn-38 con lipidos y sus metodos de uso. |
| US6620843B2 (en) * | 2001-01-19 | 2003-09-16 | Pharmagenesis | Anticancer treatment using triptolide prodrugs |
| AU2002251763B2 (en) * | 2001-01-19 | 2006-05-04 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer |
| US20030149096A1 (en) * | 2001-02-05 | 2003-08-07 | Pezzuto John M. | Cancer chemopreventative compounds and compositions and methods of treating cancers |
| HUP0303466A3 (en) * | 2001-03-06 | 2005-02-28 | Bristol Myers Squibb Company P | Method and dosage form for treating tumors by administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
| SI1372650T1 (sl) * | 2001-03-19 | 2009-04-30 | Novartis Ag | Kombinacije, ki obsegajo antidiaroično sredstvo in epotilon ali epotilonski derivat |
| US6756063B2 (en) * | 2001-03-29 | 2004-06-29 | Zoltan Laboratories, Llc | Methods and compositions for the treatment of human and animal cancers |
| US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
| US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
| WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6476068B1 (en) | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
| US6596320B1 (en) * | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
| US6816571B2 (en) * | 2002-02-06 | 2004-11-09 | L-3 Communications Security And Detection Systems Corporation Delaware | Method and apparatus for transmitting information about a target object between a prescanner and a CT scanner |
| WO2003077947A1 (en) | 2002-03-15 | 2003-09-25 | Schering Corporation | Methods of modulating cd200 receptors |
| US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
| JP4625694B2 (ja) * | 2002-05-17 | 2011-02-02 | レオ ファーマ アクティーゼルスカブ | シアノグアニジンプロドラッグ |
| US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| WO2003097602A1 (en) * | 2002-05-17 | 2003-11-27 | Leo Pharma A/S | Cyanoguanidine produgs |
| US20040038904A1 (en) * | 2002-05-21 | 2004-02-26 | Angela Ogden | Method of treating multiple sclerosis |
| US7847109B2 (en) * | 2002-05-31 | 2010-12-07 | Pharmagenesis, Inc. | Triptolide derivatives for modulation of apoptosis and immunosuppression |
| AU2003261354A1 (en) * | 2002-08-02 | 2004-02-23 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
| WO2004035032A2 (en) * | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
| US20050272698A1 (en) * | 2002-09-05 | 2005-12-08 | Daftary Gautam V | Liquid stable composition of oxazaphosphorine with mesna |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| WO2004054569A1 (en) * | 2002-12-16 | 2004-07-01 | Council Of Scientific And Industrial Research | Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings |
| US20040203034A1 (en) * | 2003-01-03 | 2004-10-14 | The University Of Chicago | Optimization of cancer treatment with irinotecan |
| JP4711947B2 (ja) * | 2003-02-03 | 2011-06-29 | ネオファーム、インコーポレイティッド | 安定な濾過滅菌性リポソームに被包化されたタキサン及び他の抗腫瘍剤 |
| ES2308208T3 (es) * | 2003-05-30 | 2008-12-01 | University Of Chicago | Metodos y composiciones para predecir la toxicidad del irinotecano. |
| US20040266808A1 (en) * | 2003-06-27 | 2004-12-30 | Kamen Barton A. | Treatment of antifolate neurotoxicity |
| DK2263694T3 (da) * | 2003-09-25 | 2013-08-26 | Astellas Pharma Inc | Antitumormiddel omfattende histon-deacetylase-inhibitoren FK228 og topoisomerase-II-inhibitoren doxorubicin |
| US7820834B2 (en) * | 2003-12-24 | 2010-10-26 | Pharmagenesis, Inc. | Triptolide 5,6-derivatives as immunomodulators and anticancer agents |
| WO2005077008A2 (en) * | 2004-02-09 | 2005-08-25 | Pharmagenesis, Inc. | Methods for isolation of triptolide compounds from tripterygium wilfordii |
| US20050187288A1 (en) * | 2004-02-20 | 2005-08-25 | Chiang Li | Beta-lapachone and methods of treating cancer |
| US20050192247A1 (en) * | 2004-02-23 | 2005-09-01 | Li Chiang J. | Method of treating cancers |
| ATE554758T1 (de) * | 2004-03-02 | 2012-05-15 | Pharmagenesis Inc | Triptolid-lacton-ring-derivate als immunmodulatoren und mittel gegen krebs |
| US20090247475A1 (en) * | 2004-03-05 | 2009-10-01 | The Regents Of The University Of California | Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies |
| US7200207B2 (en) * | 2004-03-13 | 2007-04-03 | Intrado Inc. | Communication network for providing emergency services |
| WO2005094282A2 (en) * | 2004-03-26 | 2005-10-13 | Vion Pharmaceuticals, Inc. | Combination therapy comprising cloretazinetm |
| US20050256055A1 (en) * | 2004-05-12 | 2005-11-17 | Hausheer Frederick H | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
| JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
| ATE552233T1 (de) * | 2004-08-20 | 2012-04-15 | Univ Virginia Patent Found | T-typ-calciumkanalinhibitoren |
| US20060063742A1 (en) * | 2004-09-21 | 2006-03-23 | Hausheer Frederick H | Method of treatment for or protection against lymphedema |
| TWI366459B (en) * | 2004-09-28 | 2012-06-21 | Ind Tech Res Inst | Novel hydrophilic analogs of 4,8-dihydrobenzodithiophene-4,8-diones as anticancer agents |
| US8617906B2 (en) * | 2004-10-13 | 2013-12-31 | Pharmagenesis, Inc. | Identification and screening of triptolide target molecules |
| KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
| ES2572777T3 (es) * | 2004-12-22 | 2016-06-02 | Leo Pharma A/S | Compuestos novedosos de cianoguanidina |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| AU2006326442B2 (en) * | 2005-12-13 | 2012-03-01 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| US8143236B2 (en) * | 2005-12-13 | 2012-03-27 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods |
| US8895531B2 (en) * | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
| US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| RU2009133447A (ru) * | 2007-02-09 | 2011-03-20 | Пониард Фармасьютикалз, Инк. (Us) | Дозированная форма пикоплатина |
| US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
| CN101657203B (zh) * | 2007-03-02 | 2012-09-05 | 卧龙岗大学 | 抗癌药的组合物及递送方法 |
| TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
| US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
| JP2010533714A (ja) * | 2007-07-16 | 2010-10-28 | ポニアード ファーマシューティカルズ， インコーポレイテッド | ピコプラチンのための経口製剤 |
| WO2009072004A2 (en) * | 2007-09-26 | 2009-06-11 | Gemin X Pharmaceuticals Canada, Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
| JP5696266B2 (ja) * | 2007-11-20 | 2015-04-08 | ランケナー インスティテュート フォー メディカル リサーチ | ジスルフィド化学療法剤およびその使用方法 |
| CN102006875A (zh) * | 2008-02-08 | 2011-04-06 | 帕纳德制药公司 | 吡铂和贝伐单抗治疗结直肠癌的用途 |
| CN104667279B (zh) | 2008-03-03 | 2018-10-26 | 托斯克公司 | 减少毒性的甲氨蝶呤佐剂及其使用方法 |
| WO2009111648A1 (en) * | 2008-03-05 | 2009-09-11 | Vicus Therapeutics, Llc | Compositions and methods for mucositis and oncology therapies |
| EP2252246B1 (en) * | 2008-03-14 | 2014-06-18 | Bionumerik Pharmaceuticals, Inc. | Chemoprotective methods and compositions |
| US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| EP2249825B1 (en) * | 2008-03-14 | 2015-10-07 | Bionumerik Pharmaceuticals, Inc. | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
| AU2008352603B2 (en) * | 2008-03-14 | 2012-05-31 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
| WO2010132771A1 (en) | 2009-05-15 | 2010-11-18 | Lankenau Institute For Medical Research | Methods and kits for measuring toxicity and oxidative stress in live cells |
| CA2787673A1 (en) | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| CN103221388B (zh) * | 2010-07-09 | 2016-09-28 | 维理生物技术公司 | 用于抑制转移性肿瘤生长的新型磺酰胺化合物 |
| US9271952B2 (en) * | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
| CN102871991B (zh) * | 2012-10-24 | 2014-06-18 | 中国医学科学院放射医学研究所 | 二甲双胍在对放化疗损伤起保护作用的药物中的应用 |
| EP3027212A1 (en) * | 2013-08-02 | 2016-06-08 | Children's Hospital Medical Center | Compositions and methods for treating disease states associated with activated t cells and/or b cells |
| US9470029B2 (en) | 2014-05-30 | 2016-10-18 | Pella Corporation | Casement pivot arm roller hinge |
| HRP20210543T1 (hr) | 2015-07-07 | 2021-05-14 | H. Lundbeck A/S | Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti |
| MX2018004043A (es) | 2015-10-02 | 2018-11-09 | Complexa Inc | Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados. |
| CN112469413B (zh) | 2018-05-25 | 2024-01-12 | 伊马拉公司 | 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态 |
| EP3843737A4 (en) | 2018-08-31 | 2022-06-01 | Imara Inc. | PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2806866C3 (de) * | 1978-02-17 | 1981-02-12 | Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld | Verwendung von Salzen von Dithiodialkansulfonsäuren |
| US4310515A (en) * | 1978-05-30 | 1982-01-12 | Bristol-Myers Company | Pharmaceutical compositions of cisplatin |
| US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
-
1997
- 1997-10-17 US US08/954,678 patent/US5919816A/en not_active Expired - Lifetime
-
1998
- 1998-10-16 PT PT98953570T patent/PT1033981E/pt unknown
- 1998-10-16 CN CN98810284A patent/CN1276720A/zh active Pending
- 1998-10-16 CA CA002304704A patent/CA2304704C/en not_active Expired - Fee Related
- 1998-10-16 DE DE69822659T patent/DE69822659T2/de not_active Expired - Lifetime
- 1998-10-16 WO PCT/US1998/021814 patent/WO1999020264A1/en not_active Ceased
- 1998-10-16 AT AT98953570T patent/ATE262329T1/de active
- 1998-10-16 ES ES98953570T patent/ES2213922T3/es not_active Expired - Lifetime
- 1998-10-16 JP JP2000516661A patent/JP2001520189A/ja active Pending
- 1998-10-16 DK DK98953570T patent/DK1033981T3/da active
- 1998-10-16 AU AU10908/99A patent/AU750521B2/en not_active Ceased
- 1998-10-16 EP EP98953570A patent/EP1033981B1/en not_active Expired - Lifetime
-
1999
- 1999-01-05 US US09/225,957 patent/US6040312A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,702 patent/US6057361A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,700 patent/US6048849A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,694 patent/US6066668A/en not_active Expired - Lifetime
- 1999-01-06 US US09/226,760 patent/US6040294A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,697 patent/US6046159A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,693 patent/US6066645A/en not_active Expired - Lifetime
- 1999-01-06 US US09/226,384 patent/US6043249A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,701 patent/US6046234A/en not_active Expired - Lifetime
- 1999-01-06 US US09/225,695 patent/US6040304A/en not_active Expired - Lifetime
-
2005
- 2005-10-07 JP JP2005294264A patent/JP2006070041A/ja active Pending
-
2009
- 2009-10-14 JP JP2009237143A patent/JP2010043117A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6046159A (en) | 2000-04-04 |
| AU1090899A (en) | 1999-05-10 |
| US6057361A (en) | 2000-05-02 |
| US5919816A (en) | 1999-07-06 |
| US6066645A (en) | 2000-05-23 |
| US6040294A (en) | 2000-03-21 |
| EP1033981B1 (en) | 2004-03-24 |
| DE69822659T2 (de) | 2004-08-12 |
| US6040312A (en) | 2000-03-21 |
| US6046234A (en) | 2000-04-04 |
| US6043249A (en) | 2000-03-28 |
| CA2304704A1 (en) | 1999-04-29 |
| DK1033981T3 (da) | 2004-07-12 |
| PT1033981E (pt) | 2004-08-31 |
| CN1276720A (zh) | 2000-12-13 |
| ATE262329T1 (de) | 2004-04-15 |
| JP2006070041A (ja) | 2006-03-16 |
| CA2304704C (en) | 2009-01-13 |
| AU750521B2 (en) | 2002-07-18 |
| EP1033981A1 (en) | 2000-09-13 |
| DE69822659D1 (de) | 2004-04-29 |
| JP2001520189A (ja) | 2001-10-30 |
| EP1033981A4 (en) | 2001-10-04 |
| JP2010043117A (ja) | 2010-02-25 |
| US6048849A (en) | 2000-04-11 |
| WO1999020264A1 (en) | 1999-04-29 |
| US6040304A (en) | 2000-03-21 |
| US6066668A (en) | 2000-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2213922T3 (es) | Formulaciones y metodos para reducir la toxicidad de agentes antineoplasticos. | |
| US5866169A (en) | Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate | |
| ES2204894T3 (es) | Composicion que contiene cisplatino y topotecan como agente antitumoral. | |
| ES2719052T3 (es) | Terapia de combinación con un antibiótico antitumoral | |
| KR100718946B1 (ko) | 효과적인 항종양 치료 | |
| JP2001520189A5 (enExample) | ||
| ES2333348T3 (es) | Combinaciones que comprenden epotilonas e inhibidores de la proteina tirosina quinasa y usos farmaceuticos de las mismas. | |
| RU2527531C2 (ru) | Соли изофосфорамидного иприта и его аналогов | |
| RU2334517C2 (ru) | Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство | |
| RU2004121687A (ru) | Композиции, содержащие эпотилоны, и их применение для лечения карциноидного синдрома | |
| US6025488A (en) | Formulations and methods of reducing toxicity of antineoplastic agents | |
| CA2263166C (en) | Reducing toxic effects of carboplatin using dithioethers | |
| JP2011514355A5 (enExample) | ||
| ES2774101T3 (es) | Cabazitaxel y su uso para tratar cáncer | |
| ES2255016T3 (es) | Concentrado para solucion de gemcitabina listo para el uso. | |
| US20040014730A1 (en) | Formulations and methods of reducing toxicity of anti-infective agents | |
| ES2354193T3 (es) | Utilización de epotilonas para el tratamiento del cáncer. | |
| US20120004294A1 (en) | Antitumor combination combining ave8062 and docetaxel | |
| Vet—QV03AE03 | Lanthanum Carbonate (USAN) | |
| JP2003300888A (ja) | 抗腫瘍効果増強剤 | |
| UA56306C2 (uk) | Протипухлинний препарат на основі цисдихлордіаміну платини |